AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device …
Feb 10, 2026 · Anonymous board for AstraZeneca. We’re running a short, anonymous survey to better understand how pharma reps (and others in the industry) are actually using AI today, what concerns …
Multiply Labs partners with AstraZeneca to automate cell therapy ...
Jan 27, 2026 · Multiply Labs Inc. today announced an agreement with AstraZeneca to evaluate the potential for applying good manufacturing practice, or GMP-ready, robotic systems to commercial …
AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B ...
Feb 10, 2026 · After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030” revenue target, outlining a roadmap to have more than 25 …
AstraZeneca keeps UK research site on pause, but options open
Jan 26, 2026 · AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, despite keeping its options open.
AstraZeneca joins the DTC platform pack, offering up to 70% discounts ...
Sep 26, 2025 · AstraZeneca is the latest Big Pharma to unveil a digital direct-to-consumer platform offering certain medicines at heavily reduced prices to cash-pay patients. AstraZeneca Direct will go …
January 14 2026 - JPM26: AstraZeneca's $80B revenue target 'very …
Jan 14, 2026 · Confidence is on full display at JPM, as companies talk up revenue targets, pipeline momentum, and dealmaking strength—tempered by ongoing regulatory and pricing realities.JPM26: …
AstraZeneca relaxed about relaxin drug's poor efficacy in phase 2 heart ...
Feb 11, 2026 · AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure despite abandoning work on one of two clinical-stage …
AstraZeneca | Cafepharma
Feb 20, 2026 · AstraZeneca has entered an agreement with China-based CSPC Pharmaceuticals to advance drug development programs targeting obesity and type 2 diabetes. The deal covers eight …
Sanofi, AstraZeneca and Sobi simplify Beyfortus agreements ahead of …
Apr 12, 2023 · The modification of an existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of RSV antibody Beyfortus (nirsevimab) and 'enhanced agility' in the US market.
AstraZeneca's latest amyloidosis pact with Neurimmune could reach …
Dec 4, 2025 · Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to pick up a second asset. The latest licensing deal involves NI009, a …